Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED)

Phase 2

Completed

• Conditions: Obesity

• Registration Number: NCT00482638
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

To assess the effect of MK0493 on body weight, blood pressure, mood, and appetite.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study Start: 2004-05-12
• Primary Completion: 2004-10-29
• Study Completion: 2004-10-29
• Study First Submitted: 2007-06-01
• Study First Submitted QC: 2007-06-01
• Study First Posted: 2007-06-05
• Status Verified: 2019-11
• Last Update Submitted: 2019-11-13
• Last Update Posted: 2019-11-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Patient is between 21 and 65 years
• Patient is able to read and understand and complete study questionnaires
• Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and post-study follow-up period

Read More

Exclusion Criteria

• Patient has a history of significant psychiatric disorder (such as major depression, bipolar disorder, bulimia, or anorexia nervosa
• Patient is HIV positive as determined by medical history
• Patient has undergone surgical treatment for obesity
• Patient plans to consume more than two 8 ounce glasses of grapefruit juice per day during the study
• Patient participated in another clinical study involving an investigational drug) within 3 months prior to Visit 1
• Patient is currently a heavy consumer of alcohol (>2 drinks per day or >14 drinks per week [1 drink is defined as 2 oz hard alcohol, 5 oz wine, 12 oz beer], or uses (including recreational use) any illicit drugs, or has a history of drug or alcohol abuse

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL